🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial

  2. COVID-19 Vaccine,Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial

  3. CPT Dermatophagoides pteronyssinus LETI 100 HEP/ml, Formodual 100/6 microgramos/pulsación Solución para inhalación en envase a presión, Montelukast Teva 10 mg comprimidos recubiertos con película EFG, Budesonida Aldo-Unión- 200 microgramos/pulsación suspensión para inhalación en envase a presión., Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, AVAMYS 27.5 micrograms/spray, nasal spray suspension, Formodual Nexthaler 200 microgramos/6 microgramos por inhalación po

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae

    phase 3 small molecule active

    1 trial

  4. CYCLOPHOSPHAMIDE

    Pari Pharma GmbH

    The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT

    phase 3 small molecule active

    1 trial

  5. CYCLOPHOSPHAMIDE , -, PREDNISONE , PREDNISOLONE , VINCRISTINE, DOXORUBICIN , RITUXIMAB , Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  6. CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE

    The George Institute

    Acute Lymphoblastic Leukaemia

    phase 3 small molecule active

    1 trial

  7. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  8. CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, POMALIDOMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE, CYCLOPHOSPHAMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, POMALIDOMIDE, DARATUMUMAB, GPRC5D-TARGETED CAR T, DEXAMETHASONE SODIUM PHOSPHATE, POMALIDOMIDE, TOCILIZUMAB

    Celgene Europe Limited

    Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. CYCLOPHOSPHAMIDE, Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion., DOXORUBICIN, DOCETAXEL

    Ningbo Cancer Hospital

    oestrogen-receptor (ER)-positive HER2-negative breast carcinoma

    phase 3 small molecule active

    1 trial

  10. CYCLOPHOSPHAMIDE, PACLITAXEL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, CAPECITABINE, EPIRUBICIN, IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE, CARBOPLATIN, INFLIXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, PEMBROLIZUMAB, Datopotamab deruxtecan, Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, DOXORUBICIN

    AstraZeneca AB

    Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  11. CYD Dengue Vaccine

    Sanofi Pasteur

    Dengue Fever

    phase 3 mab terminated

    1 trial

  12. CYTARABINE, CYTARABINE, Liposomal Annamycin, 0.9% Sodium Chloride Injection, USP/Ph. Eur./BP/JP

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  13. CaPre

    Grace Therapeutics

    Hypertriglyceridemia

    phase 3 small molecule completed

    2 trials

  14. Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

    Sanofi-aventis Healthcare Pty Ltd

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  15. Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB

    Eli Lilly Co.

    RET-Mutant Medullary Thyroid Cancer

    phase 3 small molecule active

    1 trial

  16. Cagrilintide

    Novo Nordisk A/S

    Overweight

    phase 3 small molecule completed

    1 trial

  17. Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  18. Candesartan

    Takeda

    Heart Failure

    phase 3 small molecule completed

    1 trial

  19. Candesartan Cilexetil

    Takeda

    Stroke

    phase 3 small molecule completed

    1 trial

  20. Candesartan and standard chronic heart disease therapy

    Takeda

    Heart Failure

    phase 3 small molecule terminated

    1 trial

  21. Cannabidiol

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder (OUD)

    phase 3 small molecule active

    1 trial

  22. Cannabidiol Oil

    Hospital Authority, Hong Kong

    Dementia, Vascular

    phase 3 small molecule active

    1 trial

  23. Capecitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  24. Capecitabine plus temozolamide

    Hospital Authority, Hong Kong

    Neuroendocrine Neoplasia's (NENs)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources